Finerenone is a novel, selective non-steroidal mineralocorticoid receptor antagonist (MRA) used for managing chronic kidney disease (CKD) in adults with type 2 diabetes. Finerenone reduces the risk of kidney function decline and cardiovascular events, offering a differentiated mechanism compared to traditional MRAs. With its targeted action and favorable safety profile, Finerenone represents a significant advancement in cardio-renal therapy.

Explore Royal Pharma as your potential partner for Finerenone API.